C92.32

Billable

Myeloid sarcoma, in relapse

HCC Category Mapping

V28HCC 17 — Metastatic Cancer and Acute Leukemia

0.368

V24HCC 9 — Lung and Other Severe Cancers

0.973

ESRDHCC 9 — Lung and Other Severe Cancers

0.000

RxHCCHCC 19 — Lymphoma and Other Cancers

0.000

What This Code Means

A solid tumor made of myeloid cancer cells that has returned after remission.

Coding Tips

•Ensure relapse is clearly documented and distinguish from initial presentation
•Note the site of the myeloid sarcoma in the medical record

Clinical Significance

Myeloid sarcoma in relapse indicates recurrence of the extramedullary myeloid tumor after previously achieving remission. Relapsed myeloid sarcoma may recur at the original site, at new extramedullary locations, or as bone marrow-based AML. Treatment of relapsed disease typically requires salvage chemotherapy and consideration of allogeneic stem cell transplantation for eligible patients.

Documentation Requirements

✓Documentation must confirm prior remission and evidence of recurrent disease, including new or growing extramedullary masses confirmed by biopsy as myeloid sarcoma.
✓Updated bone marrow biopsy to assess for concurrent AML should be documented.
✓Imaging studies showing relapse, cytogenetic/molecular testing at relapse, and salvage treatment plan must be recorded.
✓The site(s) of relapse should be clearly documented.

Commonly Confused Codes

C92.30 (myeloid sarcoma not in remission) is for primary refractory disease.C92.31 (myeloid sarcoma in remission) is for controlled disease.C92.02 (AML in relapse) should be used if relapse is purely bone marrow-based without extramedullary disease.When both myeloid sarcoma and bone marrow AML relapse occur simultaneously, both codes may be appropriate.

Code Hierarchy

└C92Myeloid leukemia └C92.3Myeloid sarcoma └C92.32Myeloid sarcoma, in relapse

└C92.32Myeloid sarcoma, in relapse